Disc Medicine

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Tests DISC-3405

For Sickle Cell Disease

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Tests DISC-0974

For Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera and Primary Myelofibrosis

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Tests DISC-3405

For Polycythemia Vera (PV)

Disc Medicine is a hematology company developing disease-modifying treatments for erythropoietic porphyrias and other rare hematologic disorders. The company's lead candidate bitopertin (a GlyT1 inhibitor for erythropoietic protoporphyria) received a Complete Response Letter from the FDA in February 2026; on October 19, 2026 Disc reported that the Phase 3 APOLLO trial met all primary and secondary endpoints and said it plans to resubmit by the end of 2026 with an FDA decision anticipated by mid-2027. Disc Medicine also develops DISC-0974 for myelofibrosis-associated anemia and DISC-3405, an anti-TMPRSS6 monoclonal antibody in a Phase 2 trial for polycythemia vera and a Phase 1b trial for sickle cell disease.

Disc Medicine has active programs across 5 rare diseases: Erythropoietic Protoporphyria, Myelodysplastic Syndromes, Myelofibrosis, Polycythemia Vera, Sickle Cell Disease. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

Yes. Disc Medicine is a rare disease specialist headquartered in Watertown, United States, founded in 2017. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Erythropoietic Protoporphyria, Myelodysplastic Syndromes, Myelofibrosis among others.

The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Disc Medicine, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

Disc Medicine was founded in 2017 and is headquartered in Watertown, United States. The company has been active for 9 years. It trades publicly under the ticker symbol IRON. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.